Diabetes medication could slash blood cancer risk

Glucagon-like peptide-1 receptor agonists could reduce the risk of hematologic malignancies among patients with Type 2 diabetes.

In a study published in JAMA Network Open, investigators used the TriNetX repository to examine the outcomes of more than 1.6 million patients with Type 2 diabetes who received either GLP-1 receptor agonists, insulin therapy or metformin between April 2005 and October 2023.

The investigators found that GLP-1 receptor agonist use was associated with a lower risk of myelodysplastic syndromes and myeloproliferative neoplasms when compared with metformin use. However, when compared with insulin therapy, GLP-1 receptor agonists resulted in a reduced risk of developing myeloid leukemia, lymphoid leukemia, non-Hodgkin lymphoma, myelodysplastic syndromes, myeloproliferative neoplasms, monoclonal gammopathy, multiple myeloma and primary amyloidosis.

Read more: JAMA Network Open

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.